| 1. |
|
|
| 2. |
|
|
| 3. |
- Gorski, Mathias, et al.
(author)
-
Genetic loci and prioritization of genes for kidney function decline derived from a meta-analysis of 62 longitudinal genome-wide association studies
- 2022
-
In: Kidney International. - : Elsevier. - 0085-2538 .- 1523-1755. ; 102:3, s. 624-639
-
Journal article (peer-reviewed)abstract
- Estimated glomerular filtration rate (eGFR) reflects kidney function. Progressive eGFR-decline can lead to kidney failure, necessitating dialysis or transplantation. Hundreds of loci from genome-wide association studies (GWAS) for eGFR help explain population cross section variability. Since the contribution of these or other loci to eGFR-decline remains largely unknown, we derived GWAS for annual eGFR-decline and meta-analyzed 62 longitudinal studies with eGFR assessed twice over time in all 343,339 individuals and in high-risk groups. We also explored different covariate adjustment. Twelve genomewide significant independent variants for eGFR-decline unadjusted or adjusted for eGFR- baseline (11 novel, one known for this phenotype), including nine variants robustly associated across models were identified. All loci for eGFR-decline were known for cross-sectional eGFR and thus distinguished a subgroup of eGFR loci. Seven of the nine variants showed variant- by-age interaction on eGFR cross section (further about 350,000 individuals), which linked genetic associations for eGFR-decline with agedependency of genetic cross- section associations. Clinically important were two to four-fold greater genetic effects on eGFR-decline in high-risk subgroups. Five variants associated also with chronic kidney disease progression mapped to genes with functional in- silico evidence (UMOD, SPATA7, GALNTL5, TPPP). An unfavorable versus favorable nine-variant genetic profile showed increased risk odds ratios of 1.35 for kidney failure (95% confidence intervals 1.03- 1.77) and 1.27 for acute kidney injury (95% confidence intervals 1.08-1.50) in over 2000 cases each, with matched controls). Thus, we provide a large data resource, genetic loci, and prioritized genes for kidney function decline, which help inform drug development pipelines revealing important insights into the age-dependency of kidney function genetics.
|
|
| 4. |
- Singh, K. P., et al.
(author)
-
Clinical standards for the management of adverse effects during treatment for TB
- 2023
-
In: The International Journal of Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1027-3719 .- 1815-7920. ; 27:7, s. 506-519
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitiv-ity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person -centred, consensus-based approach to minimise the impact of AE TB treatment.
|
|
| 5. |
- Alffenaar, J. W. C., et al.
(author)
-
Clinical standards for the dosing and management of TB drugs
- 2022
-
In: The International Journal of Tuberculosis and Lung Disease. - Paris, France : International Union Against Tuberculosis and Lung Disease. - 1027-3719 .- 1815-7920. ; 26:6, s. 483-
-
Journal article (other academic/artistic)abstract
- Background: Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance on 'best practice' for dosing and management of TB drugs.Methods: A panel of 57 global experts in the fields of microbiology, pharmacology and TB care were identified; 51 participated in a Delphi process. A 5-point Likert scale was used to score draft standards. The final document represents the broad consensus and was approved by all participants.Results: Six clinical standards were defined: Standard 1, defining the most appropriate initial dose for TB treatment; Standard 2, identifying patients who may be at risk of sub-optimal drug exposure; Standard 3, identifying patients at risk of developing drug-related toxicity and how best to manage this risk; Standard 4, identifying patients who can benefit from therapeutic drug monitoring (TDM); Standard 5, highlighting education and counselling that should be provided to people initiating TB treatment; and Standard 6, providing essential education for healthcare professionals. In addition, consensus research priorities were identified.Conclusion: This is the first consensus-based Clinical Standards for the dosing and management of TB drugs to guide clinicians and programme managers in planning and implementation of locally appropriate measures for optimal person-centred treatment to improve patient care.
|
|
| 6. |
- Schlosser, P, et al.
(author)
-
Meta-analyses identify DNA methylation associated with kidney function and damage
- 2021
-
In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 12:1, s. 7174-
-
Journal article (peer-reviewed)abstract
- Chronic kidney disease is a major public health burden. Elevated urinary albumin-to-creatinine ratio is a measure of kidney damage, and used to diagnose and stage chronic kidney disease. To extend the knowledge on regulatory mechanisms related to kidney function and disease, we conducted a blood-based epigenome-wide association study for estimated glomerular filtration rate (n = 33,605) and urinary albumin-to-creatinine ratio (n = 15,068) and detected 69 and seven CpG sites where DNA methylation was associated with the respective trait. The majority of these findings showed directionally consistent associations with the respective clinical outcomes chronic kidney disease and moderately increased albuminuria. Associations of DNA methylation with kidney function, such as CpGs at JAZF1, PELI1 and CHD2 were validated in kidney tissue. Methylation at PHRF1, LDB2, CSRNP1 and IRF5 indicated causal effects on kidney function. Enrichment analyses revealed pathways related to hemostasis and blood cell migration for estimated glomerular filtration rate, and immune cell activation and response for urinary albumin-to-creatinineratio-associated CpGs.
|
|
| 7. |
- Tin, A, et al.
(author)
-
Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus
- 2021
-
In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 12:1, s. 7173-
-
Journal article (peer-reviewed)abstract
- Elevated serum urate levels, a complex trait and major risk factor for incident gout, are correlated with cardiometabolic traits via incompletely understood mechanisms. DNA methylation in whole blood captures genetic and environmental influences and is assessed in transethnic meta-analysis of epigenome-wide association studies (EWAS) of serum urate (discovery, n = 12,474, replication, n = 5522). The 100 replicated, epigenome-wide significant (p < 1.1E–7) CpGs explain 11.6% of the serum urate variance. At SLC2A9, the serum urate locus with the largest effect in genome-wide association studies (GWAS), five CpGs are associated with SLC2A9 gene expression. Four CpGs at SLC2A9 have significant causal effects on serum urate levels and/or gout, and two of these partly mediate the effects of urate-associated GWAS variants. In other genes, including SLC7A11 and PHGDH, 17 urate-associated CpGs are associated with conditions defining metabolic syndrome, suggesting that these CpGs may represent a blood DNA methylation signature of cardiometabolic risk factors. This study demonstrates that EWAS can provide new insights into GWAS loci and the correlation of serum urate with other complex traits.
|
|
| 8. |
- Ahmerkamp, Soeren, et al.
(author)
-
Simultaneous visualization of flow fields and oxygen concentrations to unravel transport and metabolic processes in biological systems
- 2022
-
In: CELL REPORTS METHODS. - : Elsevier. - 2667-2375. ; 2:5
-
Journal article (peer-reviewed)abstract
- From individual cells to whole organisms, O-2 transport unfolds across micrometer- tomillimeter-length scales and can change within milliseconds in response to fluid flows and organismal behavior. The spatiotemporal complexity of these processes makes the accurate assessment of O-2 dynamics via currently availablemethods difficult or unreliable. Here, we present "sensPIV,'' a method to simultaneously measure O-2 concentrations and flow fields. By tracking O-2-sensitive microparticles in flow using imaging technologies that allow for instantaneous referencing, wemeasuredO(2) transportwithin (1) microfluidic devices, (2) sinkingmodel aggregates, and (3) complex colony-forming corals. Through the use of sensPIV, we find that corals use ciliarymovement to link zones of photosynthetic O-2 production to zones of O-2 consumption. SensPIV can potentially be extendable to study flow-organism interactions across many life-science and engineering applications.
|
|
| 9. |
- Kondo, Masayuki, et al.
(author)
-
Are Land-Use Change Emissions in Southeast Asia Decreasing or Increasing?
- 2022
-
In: Global Biogeochemical Cycles. - 0886-6236. ; 36:1
-
Journal article (peer-reviewed)abstract
- Southeast Asia is a region known for active land-use changes (LUC) over the past 60 years; yet, how trends in net CO2 uptake and release resulting from LUC activities (net LUC flux) have changed through past decades remains uncertain. The level of uncertainty in net LUC flux from process-based models is so high that it cannot be concluded that newer estimates are necessarily more reliable than older ones. Here, we examined net LUC flux estimates of Southeast Asia for the 1980s−2010s from older and newer sets of Dynamic Global Vegetation Model simulations (TRENDY v2 and v7, respectively), and forcing data used for running those simulations, along with two book-keeping estimates (H&N and BLUE). These estimates yielded two contrasting historical LUC transitions, such that TRENDY v2 and H&N showed a transition from increased emissions from the 1980s to 1990s to declining emissions in the 2000s, while TRENDY v7 and BLUE showed the opposite transition. We found that these contrasting transitions originated in the update of LUC forcing data, which reduced the loss of forest area during the 1990s. Further evaluation of remote sensing studies, atmospheric inversions, and the history of forestry and environmental policies in Southeast Asia supported the occurrence of peak emissions in the 1990s and declining thereafter. However, whether LUC emissions continue to decline in Southeast Asia remains uncertain as key processes in recent years, such as conversion of peat forest to oil-palm plantation, are yet to be represented in the forcing data, suggesting a need for further revision.
|
|
| 10. |
- Petzold, A., et al.
(author)
-
Advancing the FAIRness and Openness of Earth system science in Europe
- 2021
-
Conference paper (other academic/artistic)abstract
- Focused environmental research projects and continuously operating research infrastructures (RIs) designed for monitoring all subdomains of the Earth system contribute to global observing systems and serve as crucial information sources for environmental scientists in their quest for understanding and interpreting the complex Earth System and contribute to global observing systems. The EU funded ENVRI-FAIR project [1] builds on the Environmental Research Infrastructure (ENVRI) community that includes principal European producers and providers of environmental research data and services.ENVRI-FAIR targets the development and implementation of both technical frameworks and policy solutions that make subdomain boundaries irrelevant for environmental scientists and prepare Earth system science for the new Open Science paradigm. Cross-discipline harmonization and standardization activities, together with the implementation of joint data management and access structures at the RI level, facilitate the strategic coordination of observation systems required for truly interdisciplinary science. ENVRI-FAIR will ultimately create the open access ENVRI-Hub delivering environmental data and services provided by the contributing environmental RIs.The architecture and functionalities of the ENVRI-Hub are driven by the applications, use cases and user needs, and will be based on three main pillars: (1) the ENVRI Knowledge Base as the human interface to the ENVRI ecosystem; (2) the ENVRI Catalogue as the machine-actionable interface to the ENVRI ecosystem; and (3) subdomain and cross-domain use cases as demonstrators for the capabilities of service provision among ENVRIs and across Science Clusters. The architecture is designed in anticipation of interoperation with the European Open Science Cloud (EOSC) and is intended to act as a key platform for users and developers planning to include ENVRI services in their workflows.The ENVRI community objectives of sharing FAIRness experience, technologies and training as well as research products and services will be realized by means of the ENVRI-Hub. The architecture, design features, technology developments and associated policies will highlight this example of how ENVRI-FAIR is promoting FAIRness, openness and multidisciplinarity of an entire scientific area by joint developments and implementation efforts.Acknowledgment: ENVRI-FAIR has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824068.[1] Petzold, A., Asmi, A., Vermeulen, A., Pappalardo, G., Bailo, D., Schaap, D., Glaves, H. M., Bundke, U., and Zhao, Z.: ENVRI-FAIR - Interoperable environmental FAIR data and services for society, innovation and research, 15th IEEE International Conference on eScience 2019, 1-4, doi: http://doi.org/10.1109/eScience.2019.00038, 2019.
|
|
